Inno-206

Heart Failure

AstraZenecaPhase 4 / ApprovedActive

B

62/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 50/ 100
Competitive Position: 81/ 100

Competitive context

24 Active assets in the Heart Failure cohort.

Asset / Sponsor	Phase	Rating
Empagliflozin Jacob Moller	Phase 4	BB
Finerenone Hospital de Messejana Dr. Carlos Alberto Studart Gomes	Phase 4	BB
CARVEDILOL Abramson Cancer Center at Penn Medicine	Phase 3	BB
Rivaroxaban Janssen Research & Development, LLC	Phase 3	B
Cyclophosphamide AstraZeneca	Phase 4	B

View all 37 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant

BBB

Indicative ·

77 / 100

plasma cell myelomaDormant

BBB

Indicative ·

77 / 100

Recurrent Adult Acute Lymphoblastic LeukemiaDormant

BBB

Indicative ·

77 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.